A PYMNTS Company

UK: CMA accuses hydrocortisone suppliers of breaking competition law

By  |  March 5, 2019

The UK Competition and Markets Authority (CMA) has provisionally found that pharmaceutical companies Auden Mckenzie and Waymade engaged in anti-competitive behavior relating to hydrocortisone tablets.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    In a press release issued on Thursday, February 28, the CMA announced it had made a provisional finding that the two companies may have entered into an unlawful agreement.

    Under the agreement, Auden Mckenzie may have made monthly payments to Waymade in exchange for Waymade not entering the 20mg hydrocortisone market, the CMA alleged.

    Full Content: Gov UK

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.